Anika Therapeutics, Inc. (ANIK) vs Palisade Bio, Inc. (PALI)
A side-by-side comparison of Anika Therapeutics, Inc. and Palisade Bio, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
ANIK
Anika Therapeutics, Inc.
$19.31HealthcareDelayed quote: Oct 6, 2026, 12:30 PM EDT
PALI
Palisade Bio, Inc.
$1.51HealthcareDelayed quote: Oct 6, 2026, 12:30 PM EDT
Total return — ANIK vs PALI
growth of $100 · dividends reinvested · last 10yANIK -57.8% (-8.3%/yr)PALI -100.0% (-71.2%/yr)ANIK compounded faster over this window
Log scale — wide-divergence pair
ANIK PALI
ANIK vs PALI: by the numbers
- •PALI is the larger company ($261M vs $258M market cap).
- •Both run net losses; ANIK's is the smaller (-3.14% vs -6388.20% net margin).
Metrics side by side
Valuation
| Metric | ANIK | PALI |
|---|---|---|
| Forward P/E | 18.39 | N/A |
| P/S ratio | 2.14 | 522.47 |
| P/B ratio | 1.88 | 2.15 |
| EV / EBITDA | 478.05 | N/A |
| FCF yield | 0.22% | N/A |
Profitability
| Metric | ANIK | PALI |
|---|---|---|
| Gross margin | 62.16% | 0.00% |
| Operating margin | -4.24% | 0.00% |
| Net margin | -3.14% | -6388.20% |
| ROE | -2.76% | -26.24% |
| ROIC | -3.17% | -28.96% |
Growth (annualized)
| Metric | ANIK | PALI |
|---|---|---|
| Revenue CAGR (5Y) | -2.48% | N/A |
| FCF CAGR (5Y) | -39.38% | N/A |
| Total return CAGR (5Y) | -13.40% | -76.02% |
Frequently asked
- How have ANIK and PALI total returns compared?
- Over the past 10 years, ANIK delivered -8.51% and PALI delivered -71.24% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.